Residual immune dysfunction under antiretroviral therapy
- PMID: 33674177
- PMCID: PMC8410879
- DOI: 10.1016/j.smim.2021.101471
Residual immune dysfunction under antiretroviral therapy
Abstract
The usage of combination antiretroviral therapy in people with HIV (PWH) has incited profound improvement in morbidity and mortality. Yet, PWH may not experience full restoration of immune function which can manifest with non-AIDS comorbidities that frequently associate with residual inflammation and can imperil quality of life or longevity. In this review, we discuss the pathogenesis underlying chronic inflammation and residual immune dysfunction in PWH, as well as potential therapeutic interventions to ameliorate them and prevent incidence or progression of non-AIDS comorbidities. Current evidence advocates that early diagnosis and prompt initiation of therapy at high CD4 counts may represent the best available approach for an improved immune recovery in PWH.
Keywords: HIV; Inflammation; Non-AIDS comorbidities.
Copyright © 2021. Published by Elsevier Ltd.
References
-
- Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet, 2000. 355(9210): p.1131–7. - PubMed
-
- Palella FJ Jr., et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med, 1998. 338(13): p. 853–60. - PubMed
-
- Zandman-Goddard G and Shoenfeld Y, HIV and autoimmunity. Autoimmun Rev, 2002. 1(6): p. 329–37. - PubMed
-
- Cuellar ML and Espinoza LR, Rheumatic manifestations of HIV-AIDS. Baillieres Best Pract Res Clin Rheumatol, 2000. 14(3): p. 579–93. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
